Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FRS2 CRISPR Activation Plasmid (h): sc-400656-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FRS2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- FRS2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by FRS2 CRISPR Activation Plasmid (h) and FRS2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the FRS2 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FRS2 Antibody (A-5): sc-17841
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FRS2 CRISPR Activation Plasmid (h) | sc-400656-ACT | 20 µg | $397.00 |
FRS2 (fibroblast growth factor receptor substrate 2) is a membrane-proximal adaptor protein that couples activated FGFRs to downstream signaling cascades, including RAS–MAPK/ERK and PI3K–AKT pathways. Through its PTB domain and multiple tyrosine phosphorylation sites, FRS2 coordinates recruitment of GRB2/SOS and GAB1 to propagate mitogenic and survival signals that shape proliferation, differentiation, and migration. FRS2-dependent signaling is central to developmental and tissue homeostasis programs driven by FGF ligands, and aberrant FGFR–FRS2 axis activity is implicated in dysregulated growth signaling in cancer biology. As a pathway node, FRS2 is frequently studied for its role in receptor tyrosine kinase signal integration, feedback regulation, and cross-talk with other growth factor pathways.
FRS2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous FRS2 expression without altering the underlying DNA sequence.
FRS2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the FRS2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the FRS2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous FRS2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native FRS2 locus and enabling the study of FRS2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of FRS2 pathway restoration in tumor cells with silenced or reduced FRS2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.